Four of eight pancreatic cancer patients responded to VS-7375. Can Verastem repeat the result in Phase 3?
Verastem reports a 50% confirmed response rate in eight second-line pancreatic cancer patients receiving VS-7375, with a 41% rate across 22 previously treated patients at the selected 900 mg dose. The company is preparing a first-line Phase 3 study while pursuing broader development in lung and colorectal cancers.
